David Callanan
About
In The Last Decade
David Callanan
68 papers receiving 2.9k citations
Peers
Comparison fields: 5 of 89
- Ophthalmology 2.4k
- Radiology, Nuclear Medicine and Imaging 1.1k
- Molecular Biology 306
- Public Health, Environmental and Occupational Health 249
- Immunology 223
Countries citing papers authored by David Callanan
This map shows the geographic impact of David Callanan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Callanan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Callanan more than expected).
Fields of papers citing papers by David Callanan
This network shows the impact of papers produced by David Callanan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Callanan. The network helps show where David Callanan may publish in the future.
Co-authorship network of co-authors of David Callanan
This figure shows the co-authorship network connecting the top 25 collaborators of David Callanan. A scholar is included among the top collaborators of David Callanan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Callanan. David Callanan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 56 | |
| 3 | 55 | |
| 4 | 5 | |
| 5 | 6 Month Results of the READ 3 Study: Ranibizumab for Edema of the mAcula in Diabetes | 1 |
| 6 | 3 | |
| 7 | 53 | |
| 8 | The role of difluprednate ophthalmic emulsion in clinical practice | 10 |
| 9 | Topical nepafenac in the treatment of diabetic macular edema | 6 |
| 10 | Clinical Evaluation of the Safety and Efficacy of TRIESENCETM (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL for Visualization of Vitreous and Membranes in Pars Plana Vitrectomy | 1 |
| 11 | 44 | |
| 12 | Fluocinolone Acetonide Intravitreal Implant to Treat Posterior Segment Uveitis: 3–Year Results of a Multi–Center Clinical Trial | 4 |
| 13 | 20 | |
| 14 | Fluocinolone Acetonide Intravitreal Implant to Treat Posterior Uveitis: 2–year Results of a Multi–Center Clinical Trial | 5 |
| 15 | Fluocinolone Acetonide Intravitreal Implant in Patients with Diabetic Macular Edema: 12 Month Results | 4 |
| 16 | 30 | |
| 17 | 15 | |
| 18 | 21 | |
| 19 | 63 | |
| 20 | 20 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.